Taishan Medical College, Tai'an, Shandong, China.
Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, 250014, Shandong, China.
J Transl Med. 2018 Apr 6;16(1):88. doi: 10.1186/s12967-018-1461-3.
Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs.
鳞状细胞癌 (SCC) 以其高转移率和预后不良而闻名。CD109 是一种糖基磷脂酰肌醇锚定的细胞表面糖蛋白。最近，CD109 成为 SCC 的一个有潜力的生物标志物和治疗靶点。越来越多的研究报道 CD109 在多种器官的人类 SCC 中高度表达，并可能促进 SCC 的进展。在这篇综述中，我们总结了 CD109 在 SCC 中的表达模式，并讨论了 CD109 在 SCC 发病机制中的作用的分子机制。
